Human FcRH5/FcRL5 Domain Protein

Cat. No. FCR-HM20D

Description

Source	Recombinant Human FcRH5/FcRL5 Domain Protein is expressed from HEK293 with hFc (IgG1) tag at the N-terminus.
	It contains Val745-Thr850.
Accession	Q96RD9-1
Molecular Weight	The protein has a predicted MW of 36.62 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 0.1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22 μm filtered solution in PBS, 8% trehalose (pH 7.4).
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.

Assay Data

Bis-Tris PAGE



Human FcRH5 Domain on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human FcRH5 Domain is greater than 95% as determined by SEC-HPLC.

Human FcRH5/FcRL5 Domain Protein

Cat. No. FCR-HM20D

Assay Data

ELISA Data



Immobilized Human FcRH5 Domain, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-FcRH5 Antibody 1, hFc Avi Tag with the EC50 of 45.7ng/ml determined by ELISA.